Resolution of sclerodermatous myocarditis after autologous stem cell transplantation [2]

Annals of the Rheumatic Diseases

Volumn 65, Issue 9, 2006, Pages 1247-1248

  Al Mashaleh, M ^a   Bak, H ^a   Moore, J ^b   Manolios, N ^a   Englert, H ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; ELECTROCARDIOGRAPHY; HUMAN; LABORATORY TEST; LETTER; MYOCARDITIS; MYOSITIS; PRIORITY JOURNAL; SCLERODERMA; SCLERODERMATOUS MYOCARDITIS; STEM CELL TRANSPLANTATION; SYNOVITIS; TENOSYNOVITIS;

ADULT; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYOCARDITIS; SCLERODERMA, SYSTEMIC; STEM CELL TRANSPLANTATION;

EID: 33747808986     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.048405     Document Type: Letter

References (10)

1. Liangos O, Neure L, Kuhl U, Pauschinger M, Sieper J, Distler A, et al. The possible role of myocardial biopsy in systemic sclerosis. Rheumatology 2000;39:674-9.
2. Saccardi R, Tyndall A, Coghlan G, Denton C, Edan G. Consensus statement concerning cardio toxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Morrow Transplant 2004;34:877-81.
3. Van Laar JM, McSweeney PA. High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis. Best Pract Res Clin Haematol 2004;17:233-45.
4. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
5. Byers RJ, Marshall DA, Freemont AJ. Overview of the manifestations and diagnosis of scleroderma. Ann Rheum Dis 1997;56:393-4.
6. Farge D, Passweg J, Laar JM, Marjanovic Z, Besenthal C, Finke J, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis; report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-81.
7. Giortti F, Minnucci ML, Santori P, Ercoli L, Rossi M, Del Papa M, et al. Autologous peripheral stem cell transplantation in a patient with diffuse systemic sclerosis: our experience. Reumatismo 2004;56:51-6.
8. Rosen O, Massenkeil G, Hiepe F, Pest S, Hauptmann S, Radtke H, et al. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy. Bone Marrow Transplant 2001;27:657-8.
9. Toledano C, Henegar C, Ilie D, Launay D, Tiev K, Marie I, et al. Cardiopulmonary function before and after cyclophosphamide treatment in severe systemic sclerosis:comparison of monthly intravenous bolus and autologous haematopoeitic stem cell transplantation. Rev Med Intern 2005;26:444-52.
10. Law W, Thong B, Lian T, Kong K, Chng H. Acute lupus myocarditis:clinical features and outcome of an oriental case series. Lupus 2005;14:827-31.